STOK
Stoke Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-41/100
Last price
24.72
▼ 0.60 (2.37%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.63
Prev close
25.32
Day high
25.58
Day low
23.35
Volume
1.17M
Market cap
$1.57B
P/E (TTM)
—
52W range
20.32 – 40.22
Day trading desk
Gap from prior close
+1.22%
Prior close 25.32
VWAP
24.22
+2.08% from price
Relative volume
1.46×
Normal
Session range
12.60%
23.10 – 26.01
Position in range
56%
Mid range
ATR (14D)
1.34
5.42% of price
Prior day high
26.31
PDH
Prior day low
24.83
PDL
Bid / ask spread
—
Quote not published
Session volume
1.25M
Avg 852.96K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.83%
-7.8%
1M
-18.25%
-19.4%
3M
-25.36%
-29.9%
6M
-27.86%
-46.0%
YTD
-23.22%
-37.5%
1Y
-4.66%
-21.1%
3Y
+518.53%
+436.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on STOK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-3.39K
Net selling
Buy transactions
3
42.25K shares
Sell transactions
9
45.64K shares
Net transactions
+12
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
2.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | TICHO BARUCH S Officer |
SELL | 5.54K | $170.06K | Direct |
| Aug 18, 26 | KAYE EDWARD M Director |
SELL | 12.57K | $402.53K | Direct |
| Aug 18, 26 | TICHO BARUCH S Officer |
SELL | 4.77K | $152.69K | Direct |
| Aug 18, 26 | ALLAN JONATHAN General Counsel |
SELL | 2.86K | $91.64K | Direct |
| Aug 14, 26 | KAYE EDWARD M Director |
— | 26.25K | — | Direct |
| Aug 14, 26 | TICHO BARUCH S Officer |
— | 10.00K | — | Direct |
| Aug 14, 26 | ALLAN JONATHAN General Counsel |
— | 6.00K | — | Direct |
| Aug 3, 26 | TICHO BARUCH S Officer |
SELL | 7.18K | $208.38K | Direct |
| Jul 1, 26 | TICHO BARUCH S Officer |
SELL | 7.23K | $236.07K | Direct |
| Jun 16, 26 | ALLAN JONATHAN General Counsel |
SELL | 1.46K | $43.64K | Direct |
| Jun 1, 26 | TICHO BARUCH S Officer |
SELL | 1.79K | $54.89K | Direct |
| May 1, 26 | TICHO BARUCH S Officer |
SELL | 2.24K | $73.55K | Direct |
| Apr 1, 26 | TICHO BARUCH S Officer |
SELL | 1.84K | $60.03K | Direct |
| Mar 20, 26 | ALLAN JONATHAN General Counsel |
SELL | 9.29K | $313.04K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLAN JONATHAN |
General Counsel | 21.23K | Sale |
HOITT JASON |
Officer | 10.28K | Sale |
KAYE EDWARD M |
Director | 124.56K | Sale |
KRAINER ADRIAN R |
Director | 283.30K | Sale |
LEGGETT THOMAS |
Chief Financial Officer | 10.17K | Sale |
LEVIN ARTHUR A. |
Director | 22.22K | Sale |
SKORPIOS TRUST |
Trustee | — | Sale |
TICHO BARUCH S |
Officer | 20.11K | Sale |
TZIANABOS ARTHUR |
Officer and Director | 31.34K | Sale |
Fundamentals
Market cap$1.57B
Enterprise value$1.28B
Revenue (TTM)$27.59M
Gross profit$27.59M
EBITDA$-221.63M
Net income$-207.90M
EPS (TTM)$-3.38
Free cash flow$-106.20M
Total cash$292.82M
Total debt$2.68M
Book value / share$5.54
Shares outstanding64.53M
Float45.61M
Short % of float17.95%
Dividend yield0.00%
Beta (5Y)1.26
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.93
PEG ratio—
Price / sales—
Price / book4.40
EV / revenue46.48
EV / EBITDA-5.79
Gross margin100.00%
Operating margin-701.65%
Profit margin0.00%
Return on equity-61.10%
Return on assets-35.87%
Debt / equity0.78
Current ratio7.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $184.42M | $36.55M | $8.78M | $12.40M | +404.5% |
| Operating revenue | $184.42M | $36.55M | $8.78M | $12.40M | +404.5% |
| Research & development | $137.92M | $89.13M | $82.23M | $77.84M | +54.7% |
| Selling, general & admin | $67.09M | $48.79M | $41.32M | $38.92M | +37.5% |
| Total operating expense | $205.01M | $137.93M | $123.55M | $116.76M | +48.6% |
| Operating income | -$20.59M | -$101.37M | -$114.77M | -$104.36M | +79.7% |
| Net interest income | $13.76M | $12.64M | $9.91M | $3.12M | +8.8% |
| Pre-tax income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | +92.3% |
| Net income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | +92.3% |
| Net income to common | -$6.88M | -$88.98M | -$104.70M | -$101.07M | +92.3% |
| Basic EPS | -0.12 | -1.65 | -2.38 | -2.60 | +92.7% |
| Diluted EPS | -0.12 | -1.65 | -2.38 | -2.60 | +92.7% |
| EBIT | -$20.59M | -$101.37M | -$114.77M | -$104.36M | +79.7% |
| EBITDA | -$18.82M | -$99.19M | -$112.30M | -$102.81M | +81.0% |
| Basic shares | 59.22M | 54.01M | 43.99M | 38.90M | +9.6% |
| Diluted shares | 59.22M | 54.01M | 43.99M | 38.90M | +9.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $84.22M | $127.98M | $191.44M | $113.56M | -34.2% |
| Cash & short-term investments | $284.67M | $216.90M | $201.39M | $229.59M | +31.2% |
| Accounts receivable | $5.94M | $1.67M | — | — | +255.9% |
| Total current assets | $305.70M | $232.76M | $215.34M | $244.07M | +31.3% |
| Property, plant & equipment | $6.25M | $8.25M | $12.43M | $11.43M | -24.3% |
| Total assets | $418.43M | $271.56M | $228.34M | $256.07M | +54.1% |
| Total current liabilities | $57.88M | $40.06M | $30.82M | $31.39M | +44.5% |
| Total debt | $3.01M | $2.32M | $2.06M | $2.36M | +29.5% |
| Total liabilities | $65.98M | $42.53M | $68.78M | $71.22M | +55.1% |
| Retained earnings | -$497.71M | -$490.83M | -$401.85M | -$297.15M | -1.4% |
| Shareholder equity | $352.46M | $229.02M | $159.56M | $184.85M | +53.9% |
| Working capital | $247.82M | $192.70M | $184.52M | $212.68M | +28.6% |
| Net tangible assets | $352.46M | $229.02M | $159.56M | $184.85M | +53.9% |
| Shares issued | 58.92M | 54.03M | 45.92M | 39.44M | +9.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | +92.3% |
| Depreciation & amortisation | $1.77M | $2.18M | $2.47M | $1.55M | -18.7% |
| Stock-based compensation | $32.24M | $27.47M | $25.26M | $22.85M | +17.4% |
| Change in working capital | $16.35M | -$28.14M | -$6.03M | $43.02M | +158.1% |
| Operating cash flow | $45.59M | -$86.85M | -$81.07M | -$31.87M | +152.5% |
| Capital expenditure | -$670.00K | -$203.00K | -$1.62M | -$3.96M | -230.0% |
| Investing cash flow | -$186.81M | -$107.47M | $105.95M | -$45.88M | -73.8% |
| Financing cash flow | $97.39M | $131.09M | $53.01M | $46.41M | -25.7% |
| Free cash flow | $44.91M | -$87.05M | -$82.68M | -$35.83M | +151.6% |
| End cash position | $84.94M | $128.78M | $192.01M | $114.13M | -34.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $9.32M | $6.23M | $1.40M | $10.63M | $13.82M | — | +49.7% |
| Operating revenue | $9.32M | $6.23M | $1.40M | $10.63M | $13.82M | — | +49.7% |
| Research & development | $49.50M | $39.67M | $41.70M | $37.70M | $25.86M | — | +24.8% |
| Selling, general & admin | $25.25M | $19.97M | $21.15M | $16.03M | $15.26M | — | +26.4% |
| Total operating expense | $74.75M | $59.65M | $62.84M | $53.72M | $41.12M | — | +25.3% |
| Operating income | -$65.43M | -$53.42M | -$61.44M | -$43.09M | -$27.30M | — | -22.5% |
| Net interest income | $3.50M | $3.40M | $3.62M | $3.46M | $3.79M | — | +3.1% |
| Pre-tax income | -$61.62M | -$50.00M | -$57.93M | -$39.63M | -$23.48M | — | -23.2% |
| Tax provision | $0 | $0 | — | -$1.28M | $0 | $1.28M | — |
| Net income | -$61.62M | -$50.00M | -$57.93M | -$38.35M | -$23.48M | — | -23.2% |
| Net income to common | -$61.62M | -$50.00M | -$57.93M | -$38.35M | -$23.48M | — | -23.2% |
| Basic EPS | -0.93 | -0.79 | — | -0.65 | -0.40 | 1.95 | -17.7% |
| Diluted EPS | -0.93 | -0.79 | — | -0.65 | -0.40 | 1.90 | -17.7% |
| EBIT | -$65.43M | -$53.42M | -$61.44M | -$43.09M | -$27.30M | — | -22.5% |
| EBITDA | -$64.97M | -$52.98M | -$61.03M | -$42.65M | -$26.85M | — | -22.6% |
| Basic shares | 66.02M | 63.06M | — | 58.61M | 58.35M | 57.86M | +4.7% |
| Diluted shares | 66.02M | 63.06M | — | 58.61M | 58.35M | 59.40M | +4.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.00M | $155.66M | $84.22M | $83.39M | $101.47M | -29.3% |
| Cash & short-term investments | $292.82M | $343.55M | $284.67M | $248.31M | $247.71M | -14.8% |
| Accounts receivable | $7.18M | $4.45M | $5.94M | $9.25M | — | +61.3% |
| Total current assets | $322.54M | $366.68M | $305.70M | $272.44M | $269.97M | -12.0% |
| Property, plant & equipment | $6.70M | $5.89M | $6.25M | $6.79M | $6.56M | +13.8% |
| Total assets | $393.97M | $443.28M | $418.43M | $360.26M | $384.51M | -11.1% |
| Total current liabilities | $41.93M | $40.81M | $57.88M | $41.73M | $38.68M | +2.8% |
| Total debt | $1.84M | $2.43M | $3.01M | $2.91M | $2.30M | -24.2% |
| Total liabilities | $48.42M | $48.40M | $65.98M | $52.16M | $49.56M | +0.0% |
| Retained earnings | -$609.34M | -$547.72M | -$497.71M | -$439.78M | -$401.43M | -11.2% |
| Shareholder equity | $345.55M | $394.88M | $352.46M | $308.11M | $334.94M | -12.5% |
| Working capital | $280.61M | $325.88M | $247.82M | $230.71M | $231.29M | -13.9% |
| Net tangible assets | $345.55M | $394.88M | $352.46M | $308.11M | $334.94M | -12.5% |
| Shares issued | 62.40M | 62.24M | 58.92M | 55.12M | 54.72M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$61.62M | -$50.00M | -$57.93M | -$38.35M | -$23.48M | -23.2% |
| Depreciation & amortisation | $458.00K | $439.00K | $405.00K | $442.00K | $446.00K | +4.3% |
| Stock-based compensation | $10.80M | $8.75M | $9.85M | $8.04M | $7.60M | +23.4% |
| Change in working capital | -$6.54M | -$20.01M | $16.98M | -$1.12M | -$11.12M | +67.3% |
| Operating cash flow | -$56.59M | -$60.58M | -$30.45M | -$30.37M | -$25.42M | +6.6% |
| Capital expenditure | -$1.98M | -$353.00K | -$232.00K | -$132.00K | -$154.00K | -459.8% |
| Investing cash flow | $9.02M | $50.69M | -$61.06M | $9.09M | -$148.48M | -82.2% |
| Financing cash flow | $1.91M | $84.33M | $92.34M | $3.12M | $554.00K | -97.7% |
| Free cash flow | -$58.56M | -$60.94M | -$30.69M | -$30.50M | -$25.58M | +3.9% |
| End cash position | $113.72M | $159.38M | $84.94M | $84.11M | $102.27M | -28.6% |
Options analytics
Put / call volume
1.67
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
20.00
-17.9% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
3
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
20.00
0 contracts
Heaviest put OI
25.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.78 | -0.93 | -19.1% |
| Mar 2026 | -0.82 | -0.79 | +3.1% |
| Dec 2025 | -0.74 | -0.97 | -31.8% |
| Sep 2025 | -0.57 | -0.65 | -13.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.91 | 12 | $8.18M | -23.0% |
| Next quarter | -0.97 | 12 | $8.23M | +487.3% |
| Current year | -3.62 | 12 | $32.02M | -82.6% |
| Next year | -3.52 | 12 | $44.83M | +40.0% |
Analyst targets & ownership
Mean target$46.46
High target$60.00
Low target$35.00
Implied upside87.95%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy2 / 12
Hold0
Sell / Strong sell0 / 0
Held by insiders3.68%
Held by institutions125.32%
Institutions holding274
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.49
-3.02% from price
SMA 20
27.17
-10.32% from price
SMA 50
29.73
-18.02% from price
SMA 100
30.04
-17.72% from price
SMA 200
31.57
-22.80% from price
EMA 12
26.09
-5.27% from price
EMA 26
27.52
-10.18% from price
EMA 50
28.80
-14.15% from price
RSI (14)
30.2
Neutral
MACD (12,26,9)
-1.43
Hist -0.14
ATR (14)
1.34
5.50% of price
Realised vol 30D
45.2%
Annualised
Bollinger upper
30.75
20, 2σ
Bollinger lower
23.60
20, 2σ
50 / 200 cross
Death
29.73 vs 31.57
Trend bias
Below 200
-22.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.78
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
45.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-37.2%
Peak to trough
Max drawdown 5Y
-89.0%
Peak to trough
ATR 14
1.34
5.50% of price
Beta (reported)
1.26
5Y monthly, from filing
Short interest
Shares short
11.15M
Prior 12.98M
Change vs prior
-14.1%
Shorts covering
% of float
17.95%
Elevated
% of shares out
17.28%
Against total outstanding
Days to cover
13.7
Crowded exit
Float
45.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 4, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Goldman Sachs | INITIATED | — | Buy |
| May 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 20, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 19, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 18, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 18, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 17, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 17, 26 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-22
Corporate Changes & Voting Matters
8-K · 2026-04-07
Corporate Changes & Voting Matters
8-K · 2026-03-27
Headlines
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Business Wire · 17h ago
Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA
MT Newswires · 2d ago
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Business Wire · 2d ago
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Business Wire · 13d ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · 20d ago
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
GlobeNewswire · 33d ago
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Business Wire · 33d ago
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Business Wire · 35d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.